Myriad Genetics Inc. is growing its women's health portfolio by buying reproductive-testing company Counsyl Inc. for $375m. The acquisition is Myriad's largest acquisition to date and entry into the lucrative reproductive testing market.
Counsyl currently offers three products in the women's health market including Foresight, an expanded carrier screening test; Prelude, a non-invasive...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?